These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 29389239

  • 1. Effects of Bevacizumab, Ranibizumab, and Aflibercept on MicroRNA Expression in a Retinal Pigment Epithelium Cell Culture Model of Oxidative Stress.
    Dinç E, Ayaz L, Kurt AH.
    J Ocul Pharmacol Ther; 2018 May; 34(4):346-353. PubMed ID: 29389239
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
    Sheu SJ, Chao YM, Liu NC, Chan JY.
    Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J, Randoll N, Lucius R, Caliebe A, Roider J, Klettner A.
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [Abstract] [Full Text] [Related]

  • 6. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N, Terasaki H, Shirasawa M, Kawano H, Sonoda S, Yamaguchi M, Hashiguchi T, Hisatomi T, Ishibashi T, Sakamoto T.
    Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
    [Abstract] [Full Text] [Related]

  • 7. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.
    Malik D, Tarek M, Caceres del Carpio J, Ramirez C, Boyer D, Kenney MC, Kuppermann BD.
    Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i11-16. PubMed ID: 24836865
    [Abstract] [Full Text] [Related]

  • 8. Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept.
    Ranjbar M, Brinkmann MP, Zapf D, Miura Y, Rudolf M, Grisanti S.
    Cell Physiol Biochem; 2016 Jun; 38(2):737-47. PubMed ID: 26871551
    [Abstract] [Full Text] [Related]

  • 9. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
    Puddu A, Sanguineti R, Traverso CE, Viviani GL, Nicolò M.
    Eur J Ophthalmol; 2016 Aug 04; 26(5):425-30. PubMed ID: 27079208
    [Abstract] [Full Text] [Related]

  • 10. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
    Chae JB, Rho CR, Shin JA, Lyu J, Kang S.
    Korean J Ophthalmol; 2018 Aug 04; 32(4):328-338. PubMed ID: 30091312
    [Abstract] [Full Text] [Related]

  • 11. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
    Parisi L, Fuhrer R, Zinkernagel M, Enzmann V.
    Ophthalmologica; 2019 Aug 04; 241(3):137-142. PubMed ID: 30001546
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Differential Effects of Bevacizumab, Ranibizumab, and Aflibercept on the Viability and Wound Healing of Corneal Epithelial Cells.
    Kang S, Choi H, Rho CR.
    J Ocul Pharmacol Ther; 2016 Dec 04; 32(10):671-676. PubMed ID: 27827554
    [Abstract] [Full Text] [Related]

  • 15. Effects of VEGF inhibitors on human retinal pigment epithelium under high glucose and hypoxia.
    Bahrami B, Shen W, Zhu L, Zhang T, Chang A, Gillies MC.
    Clin Exp Ophthalmol; 2019 Nov 04; 47(8):1074-1081. PubMed ID: 31265210
    [Abstract] [Full Text] [Related]

  • 16. Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion.
    Ozgonul C, Dedania VS, Besirli CG.
    J Ocul Pharmacol Ther; 2018 May 04; 34(4):340-345. PubMed ID: 29447089
    [Abstract] [Full Text] [Related]

  • 17. Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy.
    De Cillà S, Farruggio S, Vujosevic S, Raina G, Filippini D, Gatti V, Clemente N, Mary D, Vezzola D, Casini G, Rossetti L, Grossini E.
    Cell Physiol Biochem; 2017 May 04; 42(5):1725-1738. PubMed ID: 28743128
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
    Klettner A, Grotelüschen S, Treumer F, Roider J, Hillenkamp J.
    Br J Ophthalmol; 2015 Jun 04; 99(6):864-9. PubMed ID: 25740806
    [Abstract] [Full Text] [Related]

  • 20. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
    Giurdanella G, Anfuso CD, Olivieri M, Lupo G, Caporarello N, Eandi CM, Drago F, Bucolo C, Salomone S.
    Biochem Pharmacol; 2015 Aug 01; 96(3):278-87. PubMed ID: 26056075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.